NCT06180733
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT06180733 |
| Title | Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II) |
| Acronym | PAM-II |
| Recruitment | Recruiting |
| Gender | female |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | University Medical Center Groningen |
| Indications | |
| Therapies | |
| Age Groups: | senior | adult |
| Covered Countries | NLD |
CKB BOOST